Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm)Tuesday, 3 November 2026 - Europe/Amsterdam

GLP-1–based therapies have transformed the treatment of metabolic diseases, evolving from first-generation peptides such as liraglutide to long-acting analogues like semaglutide. This talk will explore the scientific and technological journey behind these advances, with a focus on extending dosing intervals toward even more infrequent administration, as well as enabling oral peptide delivery.

Retatrutide, a novel GIP, GLP-1, and glucagon receptor agonist, has demonstrated efficacy and an acceptable safety profile to date across the Phase 3 TRIUMPH program (obesity, obstructive sleep apnea, and osteoarthritic knee pain) and TRANSCEND-T2D program (type 2 diabetes). This keynote delivers an in-depth CMC perspective on the manufacturing innovation enabling global-scale supply: the convergent liquid-phase peptide synthesis (LPPS) platform — encompassing fragment strategy, protecting group design, and process intensification — and the ICH Q11-grounded starting material justification framework. Together, these advances yield a commercial process of exceptional efficiency, dramatically reduced PMI, and new benchmarks for sustainable large-molecule manufacturing.